Pro Dex (PDEX) Current Deferred Revenue (2013 - 2026)

Pro Dex (PDEX) posted Current Deferred Revenue of $144000.0 for Q1 2026, down 11.66% sequentially from $163000.0 in Q4 2025.

Pro Dex (PDEX) Current Deferred Revenue (2013 - 2026) Analysis & Trends

Pro Dex has reported Current Deferred Revenue for 11 years, with the latest figure at $144000.0 in Q1 2026.

Quarterly Current Deferred Revenue changed N/A year-over-year to $144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144000.0 (changed N/A YoY) and the FY2025 annual result came in at $202000.0, up 1342.86% from the prior year.
Current Deferred Revenue eased to $144000.0 in Q1 2026 per PDEX's latest filing, from $163000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $1.0 million in Q2 2022 and troughed at $14000.0 in Q2 2024.
A 5-year average of $395272.7 and a median of $163000.0 in 2025 frame the typical range for Current Deferred Revenue.
The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue tumbled 93.64% in 2023, then jumped 1342.86% in 2025.
Over 5 years, Current Deferred Revenue stood at $851000.0 in 2022, then plunged by 93.3% to $57000.0 in 2023, then slumped by 75.44% to $14000.0 in 2024, then jumped by 1064.29% to $163000.0 in 2025, then slipped by 11.66% to $144000.0 in 2026.
According to Business Quant data, Current Deferred Revenue over the past three periods registered $144000.0, $163000.0, and $122000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	135.07 Bn	129.86 Bn	1.96 Bn
2	Becton Dickinson	52.55 Bn	51.69 Bn	2.32 Bn
3	Alcon	35.77 Bn	34.41 Bn	1.68 Bn
4	Resmed	34.02 Bn	32.56 Bn	861.22 Mn
5	Medline	29.08 Bn	26.41 Bn	2.22 Bn
6	West Pharmaceutical Services	24.82 Bn	24.39 Bn	329.20 Mn
7	Solventum	15.29 Bn	14.89 Bn	1.29 Bn
8	Cooper Companies	14.87 Bn	14.73 Bn	735.40 Mn
9	Baxter International	13.65 Bn	11.50 Bn	1.03 Bn
10	Pro Dex	208.06 Mn	197.09 Mn	6.13 Mn

Download Data